FasL (soluble) (human), (recombinant)

Product Specifications

Product Name Alternative

APO-1L, CD95L, CD178, TNFSF 6

Certification

RUO

UniProt

P48023

Source

Produced in HEK 293 cells. The extracellular domain of human FasL (APO-1L; CD95L; CD178) (aa 103-281) is fused at the N-terminus to a linker peptide (26 aa) and a FLAG ® -tag. Glycosylation of rhsFasL is similar to that of natural human FasL.

Purification

Purified by multi-step chromatography.

Stability

Stable for at least 6 months after receipt when stored at -20°C.

Concentration

0.1 mg/mL after reconstitution.

Endotoxin

<0.1EU/μg purified protein (LAL test; Associates of Cape Cod) .

Purity

≥95% (SDS-PAGE)

Activity

Kills Jurkat cells in the absence of a cross-linker. Cross-linking enhancer (see Set Prod. No. ALX-850-014) increases the activity of rhsFasL approx. 50-fold. Attention: Results using sFasL may differ from those obtained with agonistic antibodies!

Reconstitution

Reconstitute with 100μl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.

Molecular Weight

~32kDa (non-glycosylated), ~35kDa (glycosylated) (SDS-PAGE) .

Shipping Conditions

Blue Ice

Storage Conditions

-20°C

Notes

Historical lots have shown that FasL kills Jurkat cells at concentrations of >10ng/ml in the absence of a cross-linker. Historical lots have also shown an ED 50 of 50ng/ml (A20 cells) .